Related Experiment Video
Updated: Sep 4, 2025
Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
Intranasally administered melatonin core-shell polymeric nanocapsules: A promising treatment modality for cerebral
Eman A Bseiso1, Sarah A Abd El-Aal2, Maha Nasr3
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza Governorate, Egypt.
Aims:
The neurohormone melatonin (MEL) has been reported as a promising neuroprotective molecule, however it suffers pharmaceutical limitations such as poor solubility and low bioavailability, which hinder its pharmacological and clinical potential. In the current work, MEL was loaded in core-shell nanocarrier system; polymeric nanocapsules (PNCs), and assessed for its potential in cerebral ischemia reperfusion injury rat model when administered intranasally.
Key Findings:
Adopting a D-optimal factorial design, MEL-PNCs were successfully formulated using the nanoprecipitation technique. MEL-PNCs exhibited a particle size ranging from 143.5 to 444 nm, negative zeta potential values ranging from -24.2 to -38.7 mV, cumulative release % for MEL ranging from 36.79 to 41.31 % over 8 h period, with overall good storage properties. The selected MEL-PNCs formulation displayed 8-fold higher permeation than the drug solution across sheep nasal mucosa. MEL-PNCs administered intranasally decreased oxidative stress and hippocampal inflammation, and the histological examination revealed the significant restoration of hippocampal neurons.
Significance:
MEL-PNCs administered intranasally could be a promising treatment modality in brain ischemia.
